Clinical trials using antidepressants and antipsychotics. The pros and cons of placebo control;Klinische Prüfungen mit Antidepressiva und Antipsychotika. Das Für und Wider von Placebokontrollen

Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz

Volumn 48, Issue 5, 2005, Pages 541-547

  Broich, K ^a  

^a Bundesinstitut für Arzneimittel und Medizinprodukte ^*  (Germany)

Author keywords

Active comparator; Antidepressants; Antipsychotics; Clinical; Placebo control

Indexed keywords

ANTIDEPRESSANT AGENT; NEUROLEPTIC AGENT; NEW DRUG; PLACEBO;

CLINICAL STUDY; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; DRUG MONITORING; DRUG RESEARCH; DRUG TOLERABILITY; HUMAN; INFORMED CONSENT; INTERMETHOD COMPARISON; MEDICAL ASSESSMENT; MEDICAL ETHICS; METHODOLOGY; PATIENT CARE; POPULATION SIZE; PSYCHOPHARMACOLOGY; REVIEW; RISK; STANDARD; TREATMENT PLANNING;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CONTROLLED CLINICAL TRIALS; DATA INTERPRETATION, STATISTICAL; DEPRESSION; HUMANS; INFORMED CONSENT; PLACEBOS; PSYCHOTIC DISORDERS; RISK FACTORS; SAFETY; SENSITIVITY AND SPECIFICITY; SUICIDE; SUICIDE, ATTEMPTED; TIME FACTORS;

EID: 19444377834     PISSN: 14369990     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00103-005-1038-1     Document Type: Review

References (43)

1. Kloesel A, Cyran W (2002) Arzneimittelrecht - Kommentar mit amtlichen Begründungen, weiteren Materialien und einschlägigen Rechtsvorschriften sowie Sammlung gerichtlicher Entscheidungen. Deutscher Apothekerverlag, Stuttgart
2. ICH (1997) Guidance for Industry - E8 General Considerations for Clinical Trials. http://www.ich.org/pdfICH/e8.pdf
3. ICH (1998) Guidance for Industry - E9 Statistical Principles for Clinical Trials. http://www.fda.gov/cder/guidance/ICH_E9-fnl.PDF
4. ICH (2000) Guideline for Industry - Choice of Control Group and Related Issues in Clinical Trials. ICH-E10. http://www.ich.org/pdfICH/ e10step4.pdf
5. Committee for Proprietary Medicinal Products C (1998) Note for guidance on the Clinical Investigation of Medicinal Products in the Treatment of Schizophrenia. http://www.emea.eu.int. Document ID: CPMP/EWP/559/95
6. Committee for Proprietary Medicinal Products C (2002) Note For Guidance on Clinical Investigation of Medicinal Products in the Treatment of Depression (Revision 1). http://www.emea.eu.int. Document ID: Cpmp/ewp/518/97
7. Ellenberg SS, Temple R (2000) Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: practical issues and specific cases. Ann Intern Med 133:464-470
8. Leber P (2000) The use of placebo control groups in the assessment of psychiatric drugs: An historical context. Biol Psychiatry 47:699-706
9. Lewis JA, Jonsson B, Kreutz G et al. (2002) Placebo-controlled trials and the Declaration of Helsinki. Lancet 359:1337-1340
10. Temple R, Ellenberg SS (2000) Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues. Ann Intern Med 133:455-463
11. Barbui C, Violante A, Garattini S (2000) Does placebo help establish equivalence in trials of new antidepressants? Eur Psychiatr, 15:268-273
12. Michels KB, Rothman KJ (2003) Update on unethical use of placebos in randomised trials. Bioethics 17:188-204
13. Miller FG, Brody H (2002) What makes placebo-controlled trials unethical? Am J Bioeth 2:3-9
14. Puzynski S (2004) Placebo in the investigation of psychotropic drugs, especially antidepressants. Sci Eng Ethics 10:135-142
15. Rothman KJ (1996) Placebo mania. BMJ 313:3-4
16. Rothman KJ, Michels KB (1994) The continuing unethical use of placebo controls. N Engl J Med, 331:394-398
17. World Medical Association (2000) Declaration of Helsinki. Amended by the 52nd WMA General Assembly, Edinburgh, Scotland, October 2000. JAMA 284:3043-3045
18. Fleischhacker WW, Czobor P, Hummer M et al. (2003) Placebo or active control trials of antipsychotic drugs? Arch Gen Psychiatry 60:458-464
19. Garattini S, Bertele V (2001) Adjusting Europe's drug regulation to public health needs. Lancet 358:64-67
20. Otto MW, Nierenberg AA (2002) Assay sensitivity, failed clinical trials, and the conduct of science. Psychother Psychosom 71:241-243
21. Siegel JP (2000) Equivalence and noninferiority trials. Am Heart J 139:S166-170
22. Pocock S (2002) The pros and cons of noninferiority (equivalence) trials. In: Guess H, Kleinman A, Kusek J, Engel L (eds) The science of the placebo - toward an interdisciplinary research agenda. BMJ Books, London, pp 236-248
23. Laughren TP (2001) The scientific and ethical basis for placebo-controlled trials in depression and schizophrenia: An FDA perspective. Eur Psychiatry 16:418-423
24. Leber PD (1989) Hazards of inference: The active control investigation. Epilepsia 30 [Suppl 1]:S57-63; discussion S64-68
25. Walsh BT, Seidman SN, Sysko R, Gould M (2002) Placebo response in studies of major depression: Variable, substantial, and growing. Jama 287:1840-1847
26. Charney DS, Nemeroff CB, Lewis L et al. (2002) National Depressive and Manic-Depressive Association consensus statement on the use of placebo in clinical trials of mood disorders. Arch Gen Psychiatry 59:262-270
27. Fritze J, Möller HJ (2001) Design of clinical trials of antidepressants: Should a placebo control arm be included? CNS Drugs 15:755-764
28. Baldwin D, Broich K, Fritze J et al. (2003) Placebo-controlled studies in depression: Necessary, ethical and feasible. Eur Arch Psychiatry Clin Neurosci 253:22-28
29. Ellenberg SS (2003) Scientific and ethical issues in the use of placebo and active controls in clinical trials. J Bone Miner Res 18:1121-1124
30. Charney DS (2000) The use of placebos in randomized clinical trials of mood disorders: Well justified, but improvements in design are indicated. Biol Psychiatry 47:687-688
31. Michels KB (2000) The placebo problem remains. Arch Gen Psychiatry 57:321-322
32. Miller FG, Shorr AF (2002) Unnecessary use of placebo controls: The case of asthma clinical trials. Arch Intern Med 162:1673-1677
33. Khan A, Warner HA, Brown WA (2000) Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: An analysis of the Food and Drug Administration database. Arch Gen Psychiatry 57:311-317
34. Khan A, Khan S, Kolts R, Brown WA (2003) Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: Analysis of FDA reports. Am J Psychiatry 160:790-792
35. Storosum JG, van Zwieten BJ, van den Brink W et al. (2001) Suicide risk in placebo-controlled studies of major depression. Am J Psychiatry 158:1271-1275
36. Khan A, Khan SR, Leventhal RM, Brown WA (2001) Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: An analysis of the food and drug administration database. Am J Psychiatry 158:1449-1454
37. Storosum JG, van Zwieten BJ, Wohlfarth T et al. (2003) Suicide risk in placebo vs active treatment in placebo-controlled trials for schizophrenia. Arch Gen Psychiatry 60:365-368
38. Miller FG (2000) Placebo-controlled trials in psychiatric research: An ethical perspective. Biol Psychiatry 47:707-716
39. Klein DF, Thase ME, Endicott J et al. (2002) Improving clinical trials - American Society of Clinical Psychopharmacology Recommendations. Arch Gen Psychiatry 59:272-278
40. Kupfer DJ, Frank E (2002) Placebo in clinical trials for depression: complexity and necessity. JAMA 287:1853-1854
41. Möller H (2004) Sind placebokontrollierte Studien zum Wirksamkeitsbeweis von Antidepressiva notwendig? Nervenarzt 75:421-424
42. Singer EA (2004) The necessity and the value of placebo. Sci Eng Ethics 10:51-56
43. Carpenter WT Jr, Appelbaum PS, Levine RJ (2003) The Declaration of Helsinki and clinical trials: A focus on placebo-controlled trials in schizophrenia. Am J Psychiatry 160:356-362